Positive First-ever generic GLP-1 receptor agonist approved for weight loss in the U.S
as such, concluding from this study alone that patients with type 2 diabetes taking GLP-1 drugs are more likely to develop wet AMD is premature
Ethics declarations Conflict of interest F.C.S declares grants from NIH/NIDDK (P30 DK040561, U24 DK132733, and UE5 DK137285) and consulting fees from Eli Lilly, Novo Nordisk, Amgen, Boehringer Ingelheim, AstraZeneca, AbbVie, Currax, Pfizer, Doximity, MelliCell, Vida Health, Empros Pharma, Apnimed, Clearmind Medicine, and Ilant Health, all outside of the current work
For GLP-1 drugs, the risks include: Increased anxiety or panic from unstable blood sugar Triggering or worsening depression Heightened risk of obsessive eating behaviors Potential for self-esteem issues or body image dysmorphia For someone already struggling with mental health, these risks are compounded making proper medical oversight essential
Retatrutide typically continues without cycling throughout weight loss and maintenance phases
How to Take BPC-157 BPC-157 is available in several forms, each with specific applications: Injectable form: Administered subcutaneously (under the skin) near the site of injury for localised healing